Rituximab shows long-term benefits, even among people with relapsing-remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS) who stopped its use or reduced their dose, a study reported. Researchers found little evidence of disease reactivation among patients who discontinued the medication, and an adequate inflammatory disease suppression…

CXCL13, an inflammatory biomarker, may be a good marker of likely future disease activity in people with multiple sclerosis (MS), a study suggests. The study, “Intrathecally produced CXCL13: A predictive biomarker in multiple sclerosis,” was published in the Multiple Sclerosis Journal – Experimental, Translational and Clinical. Clinicians caring…

Autologous hematopoietic stem cell transplant (AHSCT) induces a reduction in relapse rate and physical disability in patients with relapsing-remitting multiple sclerosis (RRMS) who respond inadequately to other treatments, a small study suggests. The study, “Selective cognitive dysfunction and physical disability improvement after autologous hematopoietic stem cell transplantation…

Adolescents with multiple sclerosis (MS) have lower levels of fitness compared with healthy teenagers of the same age and a sex, a study suggests. Findings also demonstrated that among younger MS patients, higher levels of fitness were associated with lower disease activity and disability. The study “Youth with…

Lower levels of pro-inflammatory immune signaling proteins were found in the blood of people with relapsing-remitting multiple sclerosis (RRMS) treated with Tysabri (natalizumab) and were associated with fewer relapses and less disability, a study has found.

A bone marrow transplant may be particularly useful for those with relapsing forms of multiple sclerosis (MS) who, despite treatment with high-efficacy disease-modifying therapies (DMTs), continue to experience relapses or show signs of new lesions, experts say. According to new recommendations from the National Multiple Sclerosis Society,…

An autologous hematopoietic stem cell transplant (AHSCT) is more effective than Lemtrada (alemtuzumab) at achieving no evidence of disease activity and preventing relapses in people with relapsing-remitting multiple sclerosis (RRMS), a real-life study in Sweden reported. Adverse events (side effects) were more frequent with AHSCT over the first three…

Treatment with Tysabri (natalizumab) was more effective than Gilenya (fingolimod) in helping people with relapsing–remitting multiple sclerosis (RRMS) achieve no evidence of disease activity, a head-to-head study suggested. The study, “BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS,” was…

The brain volume of people with relapsing-remitting multiple sclerosis (RRMS) undergoes a dynamic cycle of enlargement and contractions, a new study shows. Patients with a lower volume (contractions) had less severe MS and a shorter disease duration, the study found. Overall, these findings suggest that frequent monitoring of the…

Most children and adolescents with pediatric-onset multiple sclerosis (POMS), especially those treated intravenously with a disease-modifying therapy (DMT), achieve no evidence of disease activity within two years of diagnosis, according to a real-life study from the U.S. Patients whose DMTs are infused into a vein (intravenous treatment) are more likely…

Switching to Genentech’s Ocrevus (ocrelizumab) following suboptimal treatment responses significantly lessens symptoms and leads to high rates of no evidence of disease activity in people with relapsing-remitting multiple sclerosis (RRMS), according to data from a Phase 3b clinical trial. That finding, as well as data about patients’ adherence and…

Rituximab is more effective and leads to fewer treatment discontinuations in people with multiple sclerosis (MS) than Gilenya (fingolimod) and Tecfidera (dimethyl fumarate), according to real-world data based on two years of therapy. Rituximab’s effectiveness appeared to be comparable to that of Tysabri (natalizumab), but with fewer…

I’m a fraud. Or at least I feel like one.  When writing for a site about multiple sclerosis and setting up a business focused on my diagnosis to help others in the same boat, it is a requirement that I…

An international committee of multiple sclerosis (MS) experts further clarified how guidelines, updated in 2013, should be used to classify this disease’s different states, and stressed the importance of measuring these states in a timely and consistent manner. The group’s statement, “The 2013 clinical course descriptors…

The risk of a relapse is two to three times higher in relapsing-remitting multiple sclerosis (RRMS) patients who switch from Tysabri (natalizumab) to an oral or other injectable…

A variant of the HLA-DRB1 gene — called HLA-DRB1*03 — appears to predispose people to developing multiple sclerosis (MS) in childhood, and to correlate with greater disease activity among those who do, a study in Greek patients suggests. The research also points to a protective role of one other variant of this…

A nerve cell protein found in the blood shows potential as a biomarker of neuroinflammation and future neurodegeneration in the early stages of multiple sclerosis (MS), a study reports. The protein, called serum neurofilament light chain (sNfL), is a known marker of injury to axons (nerve…

Older age at onset and evidence of active disease, like clinical relapses or inflammatory brain lesions, significantly increase the likelihood of  faster disability progression in primary progressive multiple sclerosis (PPMS), a natural history study suggests. These findings — which included active disease being seen in 31% of the 178…

Multiple sclerosis (MS) patients switching from Tysabri (natalizumab) to other disease-modifying therapies may have an increased risk of disease activity, though the risk is lower if the switch is limited to three months, a study found. The results were published in an article, “Effect of…

African-Americans and Hispanics with relapsing-remitting multiple sclerosis (RRMS) have higher blood levels of plasmablasts, a type of inflammatory immune cell that produces antibodies, than do Caucasians with this disease, a study found. The study “Black African and Latino/a identity correlates with increased plasmablasts in MS” was published in the journal…

Editor’s note: “Need to Know” is a series inspired by common forum questions and comments from readers. Have a comment or question about MS? Visit our forum. This week’s question is inspired by the forum topic “MS Lesions and Silent Inflammation” from Aug. 16, 2018. Have an experience you…

The levels of neurofilament light chain (NfL) and chitinase3-like1 (CHI3L1) in the cerebrospinal fluid — the liquid that surrounds the brain and spinal cord — serve as respective biomarkers of disease activity and progression in multiple sclerosis (MS), a study reports. Measuring levels of both proteins also helps to…

Early treatment with Tysabri (natalizumab) of patients with aggressive pediatric-onset multiple sclerosis is highly effective at achieving disease activity-free status and preventing cognitive decline, a new study shows. The study, “No evidence of disease activity including cognition (NEDA-3 plus) in naïve pediatric multiple sclerosis patients treated with natalizumab,”…

Using newer disease-modifying therapies (DMTs) as an initial treatment for children and adolescents with multiple sclerosis (MS) or clinically isolated syndrome (CIS) is associated with fewer relapses and brain lesions compared to the use of older and injectable DMTs, according to a real-world study in the U.S.

Transplanting mesenchymal stem cells (MSCs) is safe and can delay disease progression in people with active, progressive multiple sclerosis (MS), according to results from a single-center clinical trial conducted in Israel. Six months after the transplant, a considerable proportion of patients showed no signs of disease activity, compared to…

Vumerity (diroximel fumarate), taken as a 462 milligram (mg) tablet twice daily, significantly decreases disease activity in patients with relapsing-remitting multiple sclerosis (RRMS), and leads to low rates of gastrointestinal side effects, new interim data of Phase 3 trial EVOLVE-MS-1 show. The findings were presented at the 2019 Consortium…

Treatment with Tysabri (natalizumab) lowers the levels of the biomarker serum neurofilament light chain (sNfL) in patients with secondary progressive multiple sclerosis (SPMS), according to data from a Phase 3 trial. Findings also revealed that higher levels of sNfL correlated with MS lesions and disease activity prior to starting the…

Women with multiple sclerosis (MS) do not experience more relapses right after giving birth, as previously believed, according to a preliminary study. The study also revealed that mothers with MS who breastfeed their babies have a lower relapse risk compared with those who do not breastfeed. The data, “…

Blood levels of a nerve cell-derived component known as neurofilament light chain (NfL) could be used as a biomarker of disease severity and treatment response in patients with relapsing-remitting multiple sclerosis (RRMS), a new study shows. The research article, “Blood neurofilament light chain as a biomarker of MS…

A product called acrolein, which is naturally excreted by the body and possible to measure in urine and blood, may be a potential biomarker to help diagnose and evaluate disease activity in people with multiple sclerosis (MS), according to preliminary research in animal models and humans. Researchers are investigating whether acrolein…